Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy
I'm PortAI, I can summarize articles.
Brii Biosciences Ltd. reported positive results from its Phase 2 ENSURE study for hepatitis B therapy, presenting data at the AASLD The Liver Meeting® in Washington D.C. The study evaluated a combination treatment strategy using the therapeutic vaccine BRII-179, elebsiran, and PEG-IFNα. The treatment was found to be generally safe and well-tolerated. Additional Phase 2b trials are ongoing, with further data expected in 2026. However, the company cautioned that there is no guarantee of successful development or marketing of the therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments